On these premises, we hypothesized that the expression of serum miR-222-3p might contribute to early prediction of therapeutic response, clinical outcomes and adverse events for HER2-positive breast cancer patients receiving NAT. This evidence concerns the gene ERBB2 and breast carcinoma.